{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T18:16:54Z","timestamp":1768414614501,"version":"3.49.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1038\/s41409-022-01599-5","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T19:02:36Z","timestamp":1643742156000},"page":"579-585","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma"],"prefix":"10.1038","volume":"57","author":[{"given":"Brian D.","family":"Friend","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7156-2532","authenticated-orcid":false,"given":"Ibrahim N.","family":"Muhsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shreeya","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4304-935X","authenticated-orcid":false,"given":"LaQuisa C.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7707-2331","authenticated-orcid":false,"given":"Premal","family":"Lulla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4004-7837","authenticated-orcid":false,"given":"Carlos A.","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Ravi","family":"Pingali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rammurti T.","family":"Kamble","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tami D.","family":"John","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baheyeldin","family":"Salem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saleh","family":"Bhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin E.","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Craddock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghadir","family":"Sasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengfen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caridad","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Krance","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen E.","family":"Heslop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Carrum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,1]]},"reference":[{"key":"1599_CR1","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1182\/blood.V75.4.831.831","volume":"75","author":"GL Phillips","year":"1990","unstructured":"Phillips GL, Fay JW, Herzig RH, Lazarus HM, Wolff SN, Lin HS. et al. The treatment of progressive non-Hodgkin\u2019s lymphoma with intensive chemoradiotherapy and autologous marrow transplantation. Blood. 1990;75:831\u20138.","journal-title":"Blood"},{"key":"1599_CR2","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1182\/blood.V73.8.2086.2086","volume":"73","author":"GL Phillips","year":"1989","unstructured":"Phillips GL, Wolff SN, Herzig RH, Lazarus HM, Fay JW, Lin HS. et al. Treatment of progressive Hodgkin\u2019s disease with intensive chemoradiotherapy and autologous bone marrow transplantation. Blood. 1989;73:2086\u201392.","journal-title":"Blood"},{"key":"1599_CR3","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/sj.bmt.1700963","volume":"20","author":"JW Sweetenham","year":"1997","unstructured":"Sweetenham JW, Taghipour G, Milligan D, Blystad AK, Caballero D, Fassas A, et al. High-dose therapy and autologous stem cell rescue for patients with Hodgkin\u2019s disease in first relapse after chemotherapy: results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transpl. 1997;20:745\u201352.","journal-title":"Bone Marrow Transpl"},{"key":"1599_CR4","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","volume":"359","author":"N Schmitz","year":"2002","unstructured":"Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M. et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial. Lancet. 2002;359:2065\u201371.","journal-title":"Lancet"},{"key":"1599_CR5","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.bbmt.2015.02.022","volume":"21","author":"MA Perales","year":"2015","unstructured":"Perales MA, Ceberio I, Armand P, Burns LJ, Chen R, Cole PD, et al. Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2015;21:971\u201383.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1599_CR6","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1200\/JCO.1999.17.1.222","volume":"17","author":"M Andr\u00e9","year":"1999","unstructured":"Andr\u00e9 M, Henry-Amar M, Pico JL, Brice P, Blaise D, Kuentz M, et al. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin\u2019s disease induction failure: a case-control study. Soci\u00e9t\u00e9 Francaise de Greffe de Moelle. J Clin Oncol. 1999;17:222\u20139.","journal-title":"J Clin Oncol"},{"key":"1599_CR7","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1200\/JCO.1991.9.10.1871","volume":"9","author":"DE Reece","year":"1991","unstructured":"Reece DE, Barnett MJ, Connors JM, Fairey RN, Fay JW, Greer JP. et al. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin\u2019s disease [published correction appears in J Clin Oncol. 1992 Jan;10(1):170]. J Clin Oncol. 1991;9:1871\u20139.","journal-title":"J Clin Oncol"},{"key":"1599_CR8","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/sj.bmt.1701325","volume":"22","author":"JE Lancet","year":"1998","unstructured":"Lancet JE, Rapoport AP, Brasacchio R, Eberly S, Raubertas RF, Linder T, et al. Autotransplantation for relapsed or refractory Hodgkin\u2019s disease: long-term follow-up and analysis of prognostic factors. Bone Marrow Transpl. 1998;22:265\u201371.","journal-title":"Bone Marrow Transpl"},{"key":"1599_CR9","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1182\/blood.V89.3.801","volume":"89","author":"SJ Horning","year":"1997","unstructured":"Horning SJ, Chao NJ, Negrin RS, Hoppe RT, Long GD, Hu WW. et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin\u2019s disease: analysis of the Stanford University results and prognostic indices. Blood. 1997;89:801\u201313.","journal-title":"Blood"},{"key":"1599_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/sj.bmt.1702094","volume":"25","author":"A Verdeguer","year":"2000","unstructured":"Verdeguer A, Pardo N, Madero L, Martinez A, Bureo E, Fern\u00e1ndez JM, et al. Autologous stem cell transplantation for advanced Hodgkin\u2019s disease in children. Spanish group for BMT in children (GETMON), Spain. Bone Marrow Transpl. 2000;25:31\u20134.","journal-title":"Bone Marrow Transpl"},{"key":"1599_CR11","first-page":"CD009411","volume":"6","author":"M Rancea","year":"2013","unstructured":"Rancea M, Monsef I, von Tresckow B, Engert A, Skoetz N. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed\/refractory Hodgkin lymphoma. Cochrane Database Syst Rev. 2013;6:CD009411.","journal-title":"Cochrane Database Syst Rev"},{"key":"1599_CR12","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1200\/JCO.1999.17.3.825","volume":"17","author":"KS Baker","year":"1999","unstructured":"Baker KS, Gordon BG, Gross TG, Abromowitch MA, Lyden ER, Lynch JC, et al. Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin\u2019s disease in children and adolescents. J Clin Oncol. 1999;17:825\u201331.","journal-title":"J Clin Oncol"},{"key":"1599_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/sj.bmt.1700838","volume":"20","author":"P Brice","year":"1997","unstructured":"Brice P, Bouabdallah R, Moreau P, Divine M, Andr\u00e9 M, Aoudjane M, et al. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin\u2019s disease: analysis of 280 patients from the French registry. Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Mo\u00eblle. Bone Marrow Transpl. 1997;20:21\u20136.","journal-title":"Bone Marrow Transpl"},{"key":"1599_CR14","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1097\/00043426-200411000-00010","volume":"26","author":"S Stoneham","year":"2004","unstructured":"Stoneham S, Ashley S, Pinkerton CR, Wallace WH, Shankar AG, United Kingdom Children\u2019s Cancer Study Group. Outcome after autologous hemopoietic stem cell transplantation in relapsed or refractory childhood Hodgkin disease. J Pediatr Hematol Oncol. 2004;26:740\u20135.","journal-title":"J Pediatr Hematol Oncol"},{"key":"1599_CR15","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/sj.bmt.1704483","volume":"33","author":"U Popat","year":"2004","unstructured":"Popat U, Hosing C, Saliba RM, Anderlini P, van Besien K, Przepiorka D, et al. Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin\u2019s lymphoma. Bone Marrow Transpl. 2004;33:1015\u201323.","journal-title":"Bone Marrow Transpl"},{"key":"1599_CR16","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1200\/JCO.2001.19.5.1395","volume":"19","author":"A Sureda","year":"2001","unstructured":"Sureda A, Arranz R, Iriondo A, Carreras E, Lahuerta JJ, Garc\u00eda-Conde J, et al. Autologous stem-cell transplantation for Hodgkin\u2019s disease: results and prognostic factors in 494 patients from the Grupo Espa\u00f1ol de Linfomas\/Transplante Aut\u00f3logo de M\u00e9dula Osea Spanish Cooperative Group. J Clin Oncol. 2001;19:1395\u20131404.","journal-title":"J Clin Oncol"},{"key":"1599_CR17","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1182\/blood-2004-12-4689","volume":"106","author":"JC Lavoie","year":"2005","unstructured":"Lavoie JC, Connors JM, Phillips GL, Reece DE, Barnett MJ, Forrest DL. et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood. 2005;106:1473\u20131478.","journal-title":"Blood"},{"key":"1599_CR18","doi-asserted-by":"publisher","first-page":"e240","DOI":"10.3324\/haematol.2014.119214","volume":"100","author":"KB Smeland","year":"2015","unstructured":"Smeland KB, Kiserud CE, Lauritzsen GF, Fagerli U, Falk RS, Fluge \u00d8. et al. Conditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway. Haematologica. 2015;100:e240\u2013e243.","journal-title":"Haematologica"},{"key":"1599_CR19","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1002\/pbc.24851","volume":"61","author":"PD Harker-Murray","year":"2014","unstructured":"Harker-Murray PD, Drachtman RA, Hodgson DC, Chauvenet AR, Kelly KM, Cole PD. Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma. Pediatr Blood Cancer. 2014;61:579\u201386.","journal-title":"Pediatr Blood Cancer"},{"key":"1599_CR20","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.bbmt.2014.10.020","volume":"21","author":"PM Garfin","year":"2015","unstructured":"Garfin PM, Link MP, Donaldson SS, Advani RH, Luna-Fineman S, Kharbanda S, et al. Improved outcomes after autologous bone marrow transplantation for children with relapsed or refractory Hodgkin lymphoma: twenty years experience at a single institution. Biol Blood Marrow Transpl. 2015;21:326\u201334.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1599_CR21","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1200\/JCO.2004.02.121","volume":"22","author":"YE Lieskovsky","year":"2004","unstructured":"Lieskovsky YE, Donaldson SS, Torres MA, Wong RM, Amylon MD, Link MP, et al. High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin\u2019s disease: results and prognostic indices. J Clin Oncol. 2004;22:4532\u201340.","journal-title":"J Clin Oncol"},{"key":"1599_CR22","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.bbmt.2015.02.005","volume":"21","author":"Y Chen","year":"2015","unstructured":"Chen Y, Lane A, Logan B, Zhu X, Akpek G, Aljurf M, et al. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2015;21:1046\u201353.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1599_CR23","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.3324\/haematol.2012.072090","volume":"98","author":"E Van Den Neste","year":"2013","unstructured":"Van Den Neste E, Casasnovas O, Andr\u00e9 M, Touati M, Senecal D, Edeline V, et al. Classical Hodgkin\u2019s lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant. Haematologica. 2013;98:1185\u201395.","journal-title":"Haematologica"},{"key":"1599_CR24","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/j.1365-2141.2004.04964.x","volume":"125","author":"CS Portlock","year":"2004","unstructured":"Portlock CS, Donnelly GB, Qin J, Straus D, Yahalom J, Zelenetz A, et al. Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin\u2019s disease. Br J Haematol. 2004;125:701\u20138.","journal-title":"Br J Haematol"},{"key":"1599_CR25","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P McLaughlin","year":"1998","unstructured":"McLaughlin P, Grillo-L\u00f3pez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825\u201333.","journal-title":"J Clin Oncol"},{"key":"1599_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1182\/blood.V97.1.101","volume":"97","author":"P Colombat","year":"2001","unstructured":"Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V. et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood. 2001;97:101\u20136.","journal-title":"Blood"},{"key":"1599_CR27","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/S1470-2045(17)30103-1","volume":"18","author":"P Borchmann","year":"2017","unstructured":"Borchmann P, Haverkamp H, Lohri A, Mey U, Kreissl S, Greil R, et al. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin\u2019s lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group. Lancet Oncol. 2017;18:454\u201363.","journal-title":"Lancet Oncol"},{"key":"1599_CR28","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/cncr.11511","volume":"98","author":"A Younes","year":"2003","unstructured":"Younes A, Romaguera J, Hagemeister F, McLaughlin P, Rodriguez MA, Fiumara P, et al. A pilot study of rituximab in patients with recurrent, classical Hodgkin disease. Cancer. 2003;98:310\u20134.","journal-title":"Cancer"},{"key":"1599_CR29","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/stem.5530060606","volume":"6","author":"SR Newcom","year":"1988","unstructured":"Newcom SR, Kadin ME, Phillips C. L-428 Reed-Sternberg cells and mononuclear Hodgkin\u2019s cells arise from a single cloned mononuclear cell. Int J Cell Cloning. 1988;6:417\u201331.","journal-title":"Int J Cell Cloning"},{"key":"1599_CR30","doi-asserted-by":"publisher","first-page":"5920","DOI":"10.1182\/blood-2008-11-189688","volume":"113","author":"RJ Jones","year":"2009","unstructured":"Jones RJ, Gocke CD, Kasamon YL, Miller CB, Perkins B, Barber JP, et al. Circulating clonotypic B cells in classical Hodgkin lymphoma. Blood 2009;113:5920\u20136.","journal-title":"Blood"},{"issue":"Sep","key":"1599_CR31","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1093\/annonc\/mdf256","volume":"13","author":"K Spaepen","year":"2002","unstructured":"Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T, et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin\u2019s lymphoma. Ann Oncol. 2002;13(Sep):1356\u201363.","journal-title":"Ann Oncol"},{"key":"1599_CR32","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","volume":"32","author":"SF Barrington","year":"2014","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, M\u00fceller SP, et al. Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32:3048\u201358.","journal-title":"J Clin Oncol"},{"key":"1599_CR33","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. J Clin Oncol. 2014;32:3059\u201368.","journal-title":"J Clin Oncol"},{"key":"1599_CR34","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1200\/JCO.20.02224","volume":"39","author":"S Vasileiou","year":"2021","unstructured":"Vasileiou S, Lulla PD, Tzannou I, Watanabe A, Kuvalekar M, Callejas WL, et al. T-cell therapy for lymphoma using nonengineered multiantigen-targeted T cells is safe and produces durable clinical effects. J Clin Oncol. 2021;39:1415\u201325.","journal-title":"J Clin Oncol"},{"key":"1599_CR35","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","volume":"32","author":"CM Bollard","year":"2014","unstructured":"Bollard CM, Gottschalk S, Torrano V, Diouf O, Ku S, Hazrat Y, et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol. 2014;32:798\u2013808.","journal-title":"J Clin Oncol"},{"key":"1599_CR36","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1002\/cncr.32752","volume":"126","author":"D Jagadeesh","year":"2020","unstructured":"Jagadeesh D, Majhail NS, Ye, H. et al. Outcomes of rituximab\u2010BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. Cancer. 2020;126:2279\u201387.","journal-title":"Cancer"},{"key":"1599_CR37","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/sj.bmt.1703515","volume":"29","author":"T Flohr","year":"2002","unstructured":"Flohr T, Hess G, Kolbe K, Gamm H, Nolte H, Stanislawski T, et al. Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL. Bone Marrow Transpl. 2002;29:769\u201375.","journal-title":"Bone Marrow Transpl"},{"key":"1599_CR38","doi-asserted-by":"publisher","first-page":"3166","DOI":"10.1200\/JCO.2007.14.4204","volume":"26","author":"C Tarella","year":"2008","unstructured":"Tarella C, Zanni M, Magni M, Benedetti F, Patti C, Barbui T, et al. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey. J Clin Oncol. 2008;26:3166\u201375.","journal-title":"J Clin Oncol"},{"key":"1599_CR39","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with Nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N. Engl J Med. 2015;372:311\u20139.","journal-title":"N. Engl J Med"},{"key":"1599_CR40","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1182\/bloodadvances.2019000736","volume":"4","author":"T Badar","year":"2020","unstructured":"Badar T, Epperla N, Szabo A, Borson S, Vaughn J, George G, et al. Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. Blood Adv. 2020;4:47\u201354.","journal-title":"Blood Adv"},{"key":"1599_CR41","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","volume":"35","author":"R Chen","year":"2017","unstructured":"Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, et al. Phase II study of the efficacy and safety of Pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017;35:2125\u201332.","journal-title":"J Clin Oncol"},{"key":"1599_CR42","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal Phase II study of Brentuximab Vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J Clin Oncol. 2012;30:2183\u20139.","journal-title":"J Clin Oncol"},{"key":"1599_CR43","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1080\/10428199909169633","volume":"35","author":"U Keilholz","year":"1999","unstructured":"Keilholz U, Szel\u00e9nyi H, Siehl J, Foss HD, Knauf W, Thiel E, et al. Rapid regression of chemotherapy refractory lymphocyte predominant Hodgkin\u2019s disease after administration of rituximab (anti CD 20 mono- clonal antibody) and interleukin-2. Leuk Lymphoma. 1999;35:641\u20132.","journal-title":"Leuk Lymphoma"},{"key":"1599_CR44","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1055\/s-2007-984950","volume":"132","author":"HK Al-Ali","year":"2007","unstructured":"Al-Ali HK, Wittekind C, Niederwieser D. Complete remission of relapsed mixed cellularity Hodgkin\u2019s disease treated with rituximab. Dtsch Med Wochenschr. 2007;132:1688\u201391.","journal-title":"Dtsch Med Wochenschr"},{"key":"1599_CR45","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1182\/blood-2012-03-413146","volume":"119","author":"LI Gordon","year":"2012","unstructured":"Gordon LI, Longnecker R. Off-targeting oft-targeted CD20 in cHL. Blood 2012;119:4095\u20136.","journal-title":"Blood"},{"key":"1599_CR46","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1590\/1806-9282.63.09.810","volume":"63","author":"MAO Santos","year":"2017","unstructured":"Santos MAO, Lima M, de M, Santos MAO, Lima M, de M. CD20 role in pathophysiology of Hodgkin\u2019s disease. Rev da Assoc\u00e7\u00e3o M\u00e9dica Brasileira. 2017;63:810\u20133.","journal-title":"Rev da Assoc\u00e7\u00e3o M\u00e9dica Brasileira"},{"key":"1599_CR47","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1200\/JCO.2011.39.9881","volume":"31","author":"P Greaves","year":"2013","unstructured":"Greaves P, Clear A, Coutinho R, Wilson A, Matthews J, Owen A, et al. Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome. J Clin Oncol. 2013;31:256\u201362.","journal-title":"J Clin Oncol"},{"key":"1599_CR48","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.1182\/blood-2008-08-175208","volume":"113","author":"J Hiraga","year":"2009","unstructured":"Hiraga J, Tomita A, Sugimoto T, Shimada K, Ito M, Nakamura S. et al. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood. 2009;113:4885\u201393.","journal-title":"Blood"},{"key":"1599_CR49","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1158\/1078-0432.CCR-11-1429","volume":"18","author":"PC Tsai","year":"2012","unstructured":"Tsai PC, Hernandez-Ilizaliturri FJ, Bangia N, Olejniczak SH, Czuczman MS. Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2012;18:1039\u201350.","journal-title":"Clin Cancer Res"},{"key":"1599_CR50","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1080\/10428194.2018.1493732","volume":"60","author":"P Farruggia","year":"2019","unstructured":"Farruggia P, Puccio G, Locatelli F, Vetro M, Pillon M, Trizzino A, et al. Classical pediatric Hodgkin lymphoma in very young patients: the Italian experience. Leuk Lymphoma. 2019;60:696\u2013702.","journal-title":"Leuk Lymphoma"},{"key":"1599_CR51","doi-asserted-by":"publisher","first-page":"4934","DOI":"10.1182\/blood-2010-05-282756","volume":"116","author":"AJ Moskowitz","year":"2010","unstructured":"Moskowitz AJ, Yahalom J, Kewalramani T, Maragulia JC, Vanak JM, Zelenetz AD. et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood. 2010;116:4934\u20137.","journal-title":"Blood"},{"key":"1599_CR52","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1200\/JCO.2009.26.5942","volume":"28","author":"CH Moskowitz","year":"2010","unstructured":"Moskowitz CH, Sch\u00f6der H, Teruya-Feldstein J, Sima C, Iasonos A, Portlock CS, et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma. J Clin Oncol. 2010;28:1896\u2013903.","journal-title":"J Clin Oncol"},{"key":"1599_CR53","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/hon.2838","volume":"39","author":"M Hutchings","year":"2021","unstructured":"Hutchings M, Radford J, Ansell SM, Ill\u00e9s \u00c1, Sureda A, Connors JM, et al. Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: a prespecified subgroup analysis of high-risk patients from the ECHELON-1 study. Hematol Oncol. 2021;39:185\u201395.","journal-title":"Hematol Oncol"},{"key":"1599_CR54","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1080\/17474086.2018.1475226","volume":"11","author":"S Keeping","year":"2018","unstructured":"Keeping S, Wu E, Chan K, Mojebi A, Ferrante SA, Balakumaran A, et al. Pembrolizumab versus the standard of care for relapsed and refractory classical Hodgkin\u2019s lymphoma progressing after brentuximab vedotin: an indirect treatment comparison. Expert Rev Hematol. 2018;11:503\u201311.","journal-title":"Expert Rev Hematol"},{"key":"1599_CR55","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","volume":"385","author":"CH Moskowitz","year":"2015","unstructured":"Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH. et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385:1853\u201362.","journal-title":"Lancet"},{"key":"1599_CR56","doi-asserted-by":"publisher","first-page":"102089","DOI":"10.1016\/j.isci.2021.102089","volume":"24","author":"J Edelmann","year":"2021","unstructured":"Edelmann J, Dokal AD, Vilventhraraja E, Holzmann K, Britton D, Klymenko T, et al. Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways. iScience. 2021;24:102089.","journal-title":"iScience"},{"key":"1599_CR57","doi-asserted-by":"publisher","first-page":"118979","DOI":"10.1016\/j.lfs.2020.118979","volume":"268","author":"AM Gamboa-Cede\u00f1o","year":"2021","unstructured":"Gamboa-Cede\u00f1o AM, D\u00edaz M, Cristaldo N, Cristaldo N, Otero V, Schutz N, et al. Apoptotic regulator BCL-2 blockade as a potential therapy in classical Hodgkin Lymphoma. Life Sci. 2021;268:118979.","journal-title":"Life Sci"},{"key":"1599_CR58","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/bjh.14114","volume":"174","author":"Y Sawalha","year":"2016","unstructured":"Sawalha Y, Rouphail B, Jia X, Dean RM, Hill BT, Jagadeesh D, et al. Is rituximab sub-optimally dosed in indolent B cell lymphoma? Br J Haematol. 2016;174:721\u20139.","journal-title":"Br J Haematol"},{"key":"1599_CR59","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.bbmt.2020.07.014","volume":"26","author":"N Granot","year":"2020","unstructured":"Granot N, Rezvani AR, Pender BS, Storer BE, Sandmaier BM, Storb R, et al. Impact of Rituximab and Host\/Donor Fc Receptor Polymorphisms after Allogeneic Hematopoietic Cell Transplantation for CD20+ B Cell Malignancies. Biol Blood Marrow Transplant. 2020;26:1811\u201318.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1599_CR60","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1177\/1078155217702214","volume":"24","author":"VH Ha","year":"2018","unstructured":"Ha VH, Ghosh S, Leyshon C, Ryan N, Chambers CR, Stewart DA. Incidence of late onset neutropenia associated with rituximab use in B cell lymphoma patients undergoing autologous stem cell transplantation. J Oncol Pharm Pr. 2018;24:323\u201331.","journal-title":"J Oncol Pharm Pr"},{"key":"1599_CR61","doi-asserted-by":"publisher","first-page":"e2036321","DOI":"10.1001\/jamanetworkopen.2020.36321","volume":"4","author":"CL McAtee","year":"2021","unstructured":"McAtee CL, Lubega J, Underbrink K, Curry K, Msaouel P, Barrow M, et al. Association of Rituximab use with adverse events in children, adolescents, and young adults. JAMA Netw Open. 2021;4:e2036321.","journal-title":"JAMA Netw Open"},{"key":"1599_CR62","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1007\/s00277-014-2103-3","volume":"93","author":"M Witzens-Harig","year":"2014","unstructured":"Witzens-Harig M, Fo\u00e1 R, Di Rocco A, van Hazel G, Chamone DFA, Rowe JM, et al. Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study. Ann Hematol. 2014;93:1717\u201324.","journal-title":"Ann Hematol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01599-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01599-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01599-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T16:09:38Z","timestamp":1649434178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01599-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,1]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1599"],"URL":"https:\/\/doi.org\/10.1038\/s41409-022-01599-5","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,1]]},"assertion":[{"value":"7 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HEH is a current equity holder in Allovir, Marker Therapeutics; has been a member on a Board of Directors or advisory committee for Fresh Wind Biotherapies, Gilead, GlaxoSmithKline, Kiadis, Novartis, Takeda, Tessa Therapeutics; and has received research funding from Kuur Therapeutics and Tessa Therapeutics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}